Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData
Express Pharma
FEBRUARY 21, 2024
billion by 2029. “ billion by 2029. “ Gilead’s Trodelvy (sacituzumab govetican), marketed for advanced breast and bladder cancer, is seeking a label expansion for first-line NSCLC in combination with Keytruda. billion in 2023, and GlobalData projects it to surpass $14 billion by 2029. months vs. 3.7 per cent versus 12.8
111 
Let's personalize your content